Filing Flows › Entrada Therapeutics (TRDA) › Stock forecast & fair value
Entrada Therapeutics (TRDA) stock forecast and price target
Entrada Therapeutics (TRDA) trades at $4.89. 4 analysts' median price target is $20.00 (+309%), from $11.00 to $25.00.
Entrada Therapeutics' latest quarter
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for TRDA stock?
The median of 4 analysts' 12-month targets is $20.00, +309% from $4.89; the range is $11.00 to $25.00. The average rating is strong buy.
Does Entrada Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is TRDA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.